ORAMED PHARMACEUTICALS INC.
ORMPOramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
Drugs in Pipeline
9
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ORMD-0801 QD
Nonalcoholic Steatohepatitis (NASH)
ORMD-0801 (qd)
Type 2 Diabetes Mellitus
ORMD-0801 Dose # 1
Diabetes Mellitus Type 2
ORMD-0801
Diabetes Type 2
ORMD-0801 Capsules
Diabetes Mellitus Type 1
ORMD-0801 Treatment A
Type 1 Diabetes
ORMD-0801 (Insulin) capsule 8 mg BD
Diabetes Mellitus, Type 2
Oral Insulin
Non-Alcoholic Steatohepatitis (NASH)
Cohort A: ORMD-0801
T2DM (Type 2 Diabetes Mellitus)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ORMD-0801 QD | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
ORMD-0801 (qd) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ORMD-0801 Dose # 1 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
ORMD-0801 | Phase 2 | Diabetes Type 2 | - | - |
ORMD-0801 Capsules | Phase 2 | Diabetes Mellitus Type 1 | - | - |
ORMD-0801 Treatment A | Phase 2 | Type 1 Diabetes | - | - |
ORMD-0801 (Insulin) capsule 8 mg BD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Oral Insulin | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
Cohort A: ORMD-0801 | Phase 2 | T2DM (Type 2 Diabetes Mellitus) | - | - |